KALA BIO, Inc. — Director's Dealing 2017

Jul 19, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19

Reporting Person: CDK ASSOCIATES, L.L.C. (10% Owner)
Reporting Person: CAXTON CORP (10% Owner)
Reporting Person: Kovner Bruce (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Convertible Preferred Stock	$		Common Stock ()		Direct

Footnotes

F1: The Series C Preferred Stock is convertible to common stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering on a 5.2083 for one basis into the number of shares of Common Stock shown in Column 3, subject to adjustment for certain dilutive events. The shares have no expiration date.

F2: These shares represent (a) 2,834,466 shares of Series C Convertible Preferred Stock that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 23,620 shares of Series C Convertible Preferred Stock that are held in an account of an employee of Caxton Corporation or an affiliate and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.

F3: Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 3 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.